^
Association details:
| Biomarker: | PIK3CA D350G |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
Excerpt:
Also, over-expression of PIK3CA D350G and E545G, as well as the positive control mutant PIK3CA E545K, conferred vemurafenib resistance when compared to the vector or PIK3CA wild type.
DOI:
10.1158/2159-8290.CD-13-0642
